RE:RE:RE:Pretty close to an ideal situationKudos on the format of the presentation. Likely an LSA suggestion. GIven our last quarter discussions, I have to give big props for the approach on this call. The much more informative introduction and discussion of key strategy elements by PL was excellent, the slides were far more informative and discussed very well, and opening up the Q&A to all was what we have mentioned many times over. I asked a few on oncology.
It is very illuminating to see that the sell side analysts were all fixated on current sales trends and forecasts, forgetting the fact we're still not back to 100% and the new COVID variants are running amock. And all they cared about was how the NASH program, now that it's finally approved, is looking for a partner since it's a larger trial. Not a thing on TH1902! And they aren't even making the informed supposition that another reason they may want to partner and have all options open is that they see what oncology could be as far as both resource/time committment, in-house skill, and financial implications! That alone is important in negotiating a partnership because as time goes on, they will lkely have a far more confident view of what could be with SORT1+ and should they choose to, pay for a larger trial anyway. Truly clueless that they focused on two issues while the third is the most immediate value trigger.
We've speculated often that given they own 100% of the rights to EGRIFTA that they likely would need someone on the commercial/sales side globally anyway. The higher costs just pushed that forward but the writing was on the wall for that all along. I'm not so sure why the analysts didn't see that. Progressing oncology and the higher costs just moved it up to the level they need to know the finances are there and partner is there prior to initiating. I'm good with that!
SPCEO1 wrote: The headline on Bloomberg is the NASH trial is delayed and the computers are reading that and selling in pre-market trading.
PWIB123 wrote: I read the press release as mostly positive. I expected to see a small pop in pre-market trading, but I'm the stock is dropping. Makes very little sense.